Browse DPP4

Summary
SymbolDPP4
Namedipeptidyl-peptidase 4
Aliases CD26; ADCP2; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); adenosine deaminase co ......
Chromosomal Location2q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Dipeptidyl peptidase 4 soluble form: Secreted Note=Detected in the serum and the seminal fluid.; SUBCELLULAR LOCATION: Cell membrane Single-pass type II membrane protein. Apical cell membrane Single-pass type II membrane protein. Cell projection, invadopodium membrane Single-pass type II membrane protein. Cell projection, lamellipodium membrane Single-pass type II membrane protein. Cell junction Membrane raft Note=Translocated to the apical membrane through the concerted action of N- and O-Glycans and its association with lipid microdomains containing cholesterol and sphingolipids (PubMed:11773049). Redistributed to membrane rafts in T-cell in a interleukin-12-dependent activation (PubMed:12676959). Its interaction with CAV1 is necessary for its translocation to membrane rafts (PubMed:17287217). Colocalized with PTPRC in membrane rafts (PubMed:12676959). Colocalized with FAP in invadopodia and lamellipodia of migratory activated endothelial cells in collagenous matrix. Colocalized with FAP on endothelial cells of capillary-like microvessels but not large vessels within invasive breast ductal carcinoma (PubMed:16651416). Colocalized with ADA at the cell junction in lymphocyte-epithelial cell adhesion (PubMed:11772392). Colocalized with IGF2R in internalized cytoplasmic vesicles adjacent to the cell surface (PubMed:10900005).
Domain PF00930 Dipeptidyl peptidase IV (DPP IV) N-terminal region
PF00326 Prolyl oligopeptidase family
Function

Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion. In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation. When overexpressed, enhanced cell proliferation, a process inhibited by GPC3. Acts also as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones. Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline.

> Gene Ontology
 
Biological Process GO:0001662 behavioral fear response
GO:0001666 response to hypoxia
GO:0001667 ameboidal-type cell migration
GO:0002209 behavioral defense response
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0007159 leukocyte cell-cell adhesion
GO:0007626 locomotory behavior
GO:0010631 epithelial cell migration
GO:0010715 regulation of extracellular matrix disassembly
GO:0010716 negative regulation of extracellular matrix disassembly
GO:0019058 viral life cycle
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0030260 entry into host cell
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0033555 multicellular organismal response to stress
GO:0033627 cell adhesion mediated by integrin
GO:0033628 regulation of cell adhesion mediated by integrin
GO:0033631 cell-cell adhesion mediated by integrin
GO:0033632 regulation of cell-cell adhesion mediated by integrin
GO:0035640 exploration behavior
GO:0035641 locomotory exploration behavior
GO:0036293 response to decreased oxygen levels
GO:0036343 psychomotor behavior
GO:0042110 T cell activation
GO:0042596 fear response
GO:0043062 extracellular structure organization
GO:0043542 endothelial cell migration
GO:0044409 entry into host
GO:0044708 single-organism behavior
GO:0045785 positive regulation of cell adhesion
GO:0046718 viral entry into host cell
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0061744 motor behavior
GO:0070482 response to oxygen levels
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903053 regulation of extracellular matrix organization
GO:1903054 negative regulation of extracellular matrix organization
Molecular Function GO:0001618 virus receptor activity
GO:0002020 protease binding
GO:0004175 endopeptidase activity
GO:0004177 aminopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0008236 serine-type peptidase activity
GO:0008238 exopeptidase activity
GO:0008239 dipeptidyl-peptidase activity
GO:0017171 serine hydrolase activity
Cellular Component GO:0005765 lysosomal membrane
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0016324 apical plasma membrane
GO:0030027 lamellipodium
GO:0030055 cell-substrate junction
GO:0030139 endocytic vesicle
GO:0031252 cell leading edge
GO:0031253 cell projection membrane
GO:0031256 leading edge membrane
GO:0031258 lamellipodium membrane
GO:0045121 membrane raft
GO:0045177 apical part of cell
GO:0046581 intercellular canaliculus
GO:0071437 invadopodium
GO:0071438 invadopodium membrane
GO:0098589 membrane region
GO:0098852 lytic vacuole membrane
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04974 Protein digestion and absorption
Reactome R-HSA-400508: Incretin synthesis, secretion, and inactivation
R-HSA-392499: Metabolism of proteins
R-HSA-2980736: Peptide hormone metabolism
R-HSA-381771: Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
R-HSA-400511: Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
Summary
SymbolDPP4
Namedipeptidyl-peptidase 4
Aliases CD26; ADCP2; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); adenosine deaminase co ......
Chromosomal Location2q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DPP4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between DPP4 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26075911MelanomaInhibit immunity (infiltration); decrease the efficacy of immunotherapyHere we show that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors.
29213079Mesothelioma; MelanomaPromote immunity (T cell function)Further analysis revealed that CD26high cells have a rich chemokine receptor profile (including CCR2 and CCR5), profound cytotoxicity (Granzyme B and CD107A), resistance to apoptosis (c-KIT and Bcl2), and enhanced stemness (β-catenin and Lef1). These properties license CD26high T cells with a natural capacity to traffic to, regress and survive in solid tumors.
Summary
SymbolDPP4
Namedipeptidyl-peptidase 4
Aliases CD26; ADCP2; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); adenosine deaminase co ......
Chromosomal Location2q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DPP4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDPP4
Namedipeptidyl-peptidase 4
Aliases CD26; ADCP2; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); adenosine deaminase co ......
Chromosomal Location2q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DPP4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7340.0399
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7630.306
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7020.178
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5370.23
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2140.387
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3160.852
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2160.743
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7640.546
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3850.779
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4520.783
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0580.664
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5990.0115
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DPP4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.75.5-1.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.67.4-4.80.565
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolDPP4
Namedipeptidyl-peptidase 4
Aliases CD26; ADCP2; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); adenosine deaminase co ......
Chromosomal Location2q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DPP4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDPP4
Namedipeptidyl-peptidase 4
Aliases CD26; ADCP2; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); adenosine deaminase co ......
Chromosomal Location2q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DPP4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DPP4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDPP4
Namedipeptidyl-peptidase 4
Aliases CD26; ADCP2; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); adenosine deaminase co ......
Chromosomal Location2q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DPP4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDPP4
Namedipeptidyl-peptidase 4
Aliases CD26; ADCP2; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); adenosine deaminase co ......
Chromosomal Location2q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DPP4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDPP4
Namedipeptidyl-peptidase 4
Aliases CD26; ADCP2; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); adenosine deaminase co ......
Chromosomal Location2q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DPP4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDPP4
Namedipeptidyl-peptidase 4
Aliases CD26; ADCP2; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); adenosine deaminase co ......
Chromosomal Location2q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DPP4 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting DPP4.
ID Name Drug Type Targets #Targets
DB01076AtorvastatinSmall MoleculeAHR, DPP4, HMGCR3
DB01261SitagliptinSmall MoleculeDPP41
DB018842-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-OneSmall MoleculeDPP41
DB020045-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-AmineSmall MoleculeDPP41
DB03253(2s)-Pyrrolidin-2-YlmethylamineSmall MoleculeDPP41
DB036604-Iodo-L-phenylalanineSmall MoleculeDPP41
DB04491Diisopropylphosphono GroupSmall MoleculeCFB, DPP42
DB045771-(1-phenylcyclopentyl)methylamineSmall MoleculeDPP41
DB04578(S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamideSmall MoleculeDPP41
DB04876VildagliptinSmall MoleculeDPP41
DB05001PSN9301Small MoleculeDPP41
DB06127KRP-104Small MoleculeDPP41
DB06203AlogliptinSmall MoleculeDPP41
DB06335SaxagliptinSmall MoleculeDPP41
DB06880(1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINESmall MoleculeDPP41
DB06939N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDESmall MoleculeDPP41
DB06993(2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amineSmall MoleculeDPP41
DB06994(2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amineSmall MoleculeDPP41
DB07015(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amineSmall MoleculeDPP41
DB07021(7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c']dipyridin-7-amineSmall MoleculeDPP41
DB07067(2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINESmall MoleculeDPP41
DB07072(1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINESmall MoleculeDPP41
DB07081(2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINESmall MoleculeDPP41
DB07092(2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDESmall MoleculeDPP41
DB07135(2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDESmall MoleculeDPP41
DB07154(3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONESmall MoleculeDPP41
DB071814'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamideSmall MoleculeDPP41
DB07193(2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amineSmall MoleculeDPP41
DB072397-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrileSmall MoleculeDPP41
DB072714-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-oneSmall MoleculeDPP41
DB07328METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATESmall MoleculeDPP41
DB07356(1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINESmall MoleculeDPP41
DB074121-biphenyl-2-ylmethanamineSmall MoleculeDPP41
DB07465(1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrileSmall MoleculeDPP41
DB07482(2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDESmall MoleculeDPP41
DB07666(3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINESmall MoleculeDPP41
DB07779N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDESmall MoleculeDPP41
DB07830(4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONESmall MoleculeDPP41
DB07851(3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINESmall MoleculeDPP41
DB080241-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILESmall MoleculeDPP41
DB08044(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINESmall MoleculeDPP41
DB08051(2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINESmall MoleculeDPP41
DB08164(3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINESmall MoleculeDPP41
DB08382GosogliptinSmall MoleculeDPP41
DB08429N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamideSmall MoleculeDPP41
DB08445(3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINESmall MoleculeDPP41
DB085046-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUMSmall MoleculeDPP41
DB085307-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONESmall MoleculeDPP41
DB085882-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILESmall MoleculeDPP41
DB086724-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDESmall MoleculeDPP41
DB087432-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILESmall MoleculeDPP41
DB08882LinagliptinSmall MoleculeDPP41
DB11723DutogliptinSmall MoleculeDPP41